Literature DB >> 12523466

Celecoxib in human milk: a case report.

David C Knoppert1, Diana Stempak, Sylvain Baruchel, Gideon Koren.   

Abstract

Many women of reproductive age take the nonsteroidal antiinflammatory drug celecoxib. No data exist, however, regarding its transfer into human breast milk and safety for breastfed infants. We had the opportunity to obtain such data when a woman who was breastfeeding her infant daughter underwent emergency surgery to remove a gangrenous appendix. She received four doses of oral celecoxib 100 mg and did not breastfeed her daughter for 48 hours after taking the last dose. We analyzed samples of her breast milk and found a concentration of 133 ng/ml at approximately 5 hours after a 100-mg dose and an elimination half-life of 4.0-6.5 hours. This initial report, which should be substantiated and expanded, provides information that can help counsel parents about breastfeeding and celecoxib.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12523466     DOI: 10.1592/phco.23.1.97.31925

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Quantification of infant exposure to celecoxib through breast milk.

Authors:  Sharon J Gardiner; Matthew P Doogue; Mei Zhang; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

2.  Transfer of rofecoxib into human milk.

Authors:  Sharon J Gardiner; Evan J Begg; Mei Zhang; Ruth C E Hughes
Journal:  Eur J Clin Pharmacol       Date:  2005-06-10       Impact factor: 2.953

3.  Impact of transmammary-delivered meloxicam on biomarkers of pain and distress in piglets after castration and tail docking.

Authors:  Jessica L Bates; Locke A Karriker; Matthew L Stock; Kelly M Pertzborn; Luke G Baldwin; Larry W Wulf; C J Lee; Chong Wang; Johann F Coetzee
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.